...of it," said Nam. Qurient's KDDF grants were for preclinical and clinical studies of its Q203... ...develop compounds discovered by and licensed from the Institut Pasteur Korea and other research facilities. Q203...
...the IPO proceeds for clinical development of lead compounds Q301 to treat atopic dermatitis and Q203... ...multi-drug resistant tuberculosis. Q301 is a topical leukotriene inhibitor that has completed Phase IIa testing. Q203...
...Qurient granted Infectex exclusive rights to develop and commercialize preclinical tuberculosis compound Q203 in Russia, Armenia... ...the government of South Korea. The company has rights to the compound from the institute. Q203...
...replication with low nanomolar potency and were not cytotoxic to host cells. The best compound, Q203... ...lung pathology compared with vehicle in MDR M. tuberculosis-infected mice. In vitro and in mice, Q203...
...institute spinout. 1 Qurient plans to start a Phase I trial of the TB compound, Q203... ...Medicine , a team led by IPK principal investigator Kevin Pethe outlined the discovery of Q203... ...activity against cultured M. tuberculosis to confirm that the compounds had a direct antimicrobial effect. Q203...
